Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

BlyS: a potential hallmark of multiple myeloma.

Wang P, Qian L, Yuan X, Hu C, Wang L, Huang Q, Miao P, Yu Q, Ma Y, Zhang J, Chen X, Liu B, Shen L, Zhang D.

Front Biosci (Landmark Ed). 2013 Jan 1;18:324-31.

PMID:
23276925
[PubMed - indexed for MEDLINE]
2.

B-Lymphocyte stimulator: a new biomarker for multiple myeloma.

Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S.

Eur J Haematol. 2009 Apr;82(4):267-76. doi: 10.1111/j.1600-0609.2008.01203.x. Epub 2009 Jan 31.

PMID:
19187273
[PubMed - indexed for MEDLINE]
3.

BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells.

Xu G, Shen XJ, Pu J, Chu SP, Wang XD, Wu XH, Sun CJ, Zhang X, Zhu BL, Ju SQ.

Cytokine. 2012 Nov;60(2):505-13. doi: 10.1016/j.cyto.2012.06.317. Epub 2012 Jul 31.

PMID:
22850273
[PubMed - indexed for MEDLINE]
4.

The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.

Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, Fadeel B, Zheng C.

Mol Immunol. 2010 Aug;47(14):2388-96. doi: 10.1016/j.molimm.2010.05.003. Epub 2010 Jun 9.

PMID:
20542572
[PubMed - indexed for MEDLINE]
5.

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.

Blood. 2004 Apr 15;103(8):3158-66. Epub 2003 Dec 11.

PMID:
15070698
[PubMed - indexed for MEDLINE]
Free Article
6.

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K.

Blood. 2004 Apr 15;103(8):3148-57. Epub 2003 Dec 4.

PMID:
15070697
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.

PMID:
19436050
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.

Kupisiewicz K.

Dan Med Bull. 2011 May;58(5):B4277. Review.

PMID:
21535989
[PubMed - indexed for MEDLINE]
Free Article
9.

Increased fatty acid synthase as a potential therapeutic target in multiple myeloma.

Wang WQ, Zhao XY, Wang HY, Liang Y.

J Zhejiang Univ Sci B. 2008 Jun;9(6):441-7. doi: 10.1631/jzus.B0740640.

PMID:
18543396
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].

Wang H, Liu X, Xu B.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):531-7. Chinese.

PMID:
18549623
[PubMed - indexed for MEDLINE]
11.

[Expression of B lymphocyte stimulator and its receptors in multiple myeloma cells: a mechanism for the cell growth and survival].

Pu J, Wang YG, Wang M, Yuan HX, Ju SQ.

Zhonghua Xue Ye Xue Za Zhi. 2009 Apr;30(4):247-50. Chinese.

PMID:
19731825
[PubMed - indexed for MEDLINE]
12.

The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.

Landau DA, Rosenzwajg M, Saadoun D, Klatzmann D, Cacoub P.

Ann Rheum Dis. 2009 Mar;68(3):337-44. doi: 10.1136/ard.2007.085910. Epub 2008 Apr 23.

PMID:
18434450
[PubMed - indexed for MEDLINE]
13.

Correlation of expression levels of BLyS and its receptors with multiple myeloma.

Ju S, Wang Y, Ni H, Wang X, Jiang P, Kong X, Zhong R.

Clin Biochem. 2009 Mar;42(4-5):387-99. doi: 10.1016/j.clinbiochem.2008.10.024. Epub 2008 Nov 11.

PMID:
19028483
[PubMed - indexed for MEDLINE]
14.

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA.

Int J Cancer. 2012 Sep 15;131(6):1466-71. doi: 10.1002/ijc.27342. Epub 2011 Dec 21.

PMID:
22052418
[PubMed - indexed for MEDLINE]
15.

The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.

Biochem Pharmacol. 2012 Aug 15;84(4):451-8. doi: 10.1016/j.bcp.2012.05.019. Epub 2012 Jun 9.

PMID:
22687624
[PubMed - indexed for MEDLINE]
16.

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F.

Blood. 1999 May 1;93(9):3064-73.

PMID:
10216103
[PubMed - indexed for MEDLINE]
Free Article
17.

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF.

Blood. 2004 Jan 15;103(2):689-94. Epub 2003 Sep 25.

PMID:
14512299
[PubMed - indexed for MEDLINE]
Free Article
18.

New targets of PS-341: BAFF and APRIL.

Li W, Li J, Su C, Zou WY, Luo S.

Med Oncol. 2010 Jun;27(2):439-45. doi: 10.1007/s12032-009-9230-z. Epub 2009 May 19.

PMID:
19452288
[PubMed - indexed for MEDLINE]
19.

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.

Perez LE, Parquet N, Meads M, Anasetti C, Dalton W.

Eur J Haematol. 2010 Mar;84(3):212-22. doi: 10.1111/j.1600-0609.2009.01381.x. Epub 2009 Nov 17.

PMID:
19922463
[PubMed - indexed for MEDLINE]
20.

The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.

Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V.

Blood. 2007 Mar 15;109(6):2557-64. Epub 2006 Nov 21.

PMID:
17119117
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk